Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Lucid Group Inc (LCID) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Lucid Group Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Lucid Group Inc trades at $4.65 (market cap $1.80B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 4.5× Lucid Group Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Lucid Group Inc nearer its low. Which is the better fit depends on your goals.
| BIO | LCID | |
|---|---|---|
Market Cap | $8.04B | $1.80B |
Sector | Health | Consumer Cyclical |
52-Week High | $339.75 | $31.30 |
52-Week Low | $241.71 | $4.62 |
Enterprise Value | $7.85B | $4.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Lucid Group (LCID) trades at $5.51, down 0.72% amid significant volatility following bankruptcy rumors that the company denied on July 14, 2026. The stock shows bearish technical signals with negative financial metrics including a -239.81% net income margin and consistent earnings misses. Recent news highlights restructuring advisory engagement and multiple class-action lawsuits filed against the company, creating substantial investor uncertainty.
The outlook remains highly speculative with severe fundamental challenges including massive losses, negative cash flow, and declining revenue. While analyst consensus targets $10.50, representing 91% upside, the overwhelming hold/sell ratings and ongoing legal pressures suggest significant downside risk. Investment requires high risk tolerance given the company's financial distress and competitive EV market pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →
